These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 16842237)

  • 21. Checkpoint kinase inhibitors: a patent review (2009 - 2010).
    Lainchbury M; Collins I
    Expert Opin Ther Pat; 2011 Aug; 21(8):1191-210. PubMed ID: 21599421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of chk1 and plk1 silencing on radiation- or cisplatin-induced cytotoxicity in human malignant cells.
    Gao Q; Huang X; Tang D; Cao Y; Chen G; Lu Y; Zhuang L; Wang S; Xu G; Zhou J; Ma D
    Apoptosis; 2006 Oct; 11(10):1789-800. PubMed ID: 16927022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms.
    King C; Diaz HB; McNeely S; Barnard D; Dempsey J; Blosser W; Beckmann R; Barda D; Marshall MS
    Mol Cancer Ther; 2015 Sep; 14(9):2004-13. PubMed ID: 26141948
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells.
    Wang FZ; Fei HR; Cui YJ; Sun YK; Li ZM; Wang XY; Yang XY; Zhang JG; Sun BL
    Apoptosis; 2014 Sep; 19(9):1389-98. PubMed ID: 24928205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chk1 instability is coupled to mitotic cell death of p53-deficient cells in response to virus-induced DNA damage signaling.
    Jurvansuu J; Fragkos M; Ingemarsdotter C; Beard P
    J Mol Biol; 2007 Sep; 372(2):397-406. PubMed ID: 17663993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition.
    Meng F; Bhupathi D; Sun JD; Liu Q; Ahluwalia D; Wang Y; Matteucci MD; Hart CP
    BMC Cancer; 2015 May; 15():422. PubMed ID: 25994202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cadmium-induced DNA damage triggers G(2)/M arrest via chk1/2 and cdc2 in p53-deficient kidney proximal tubule cells.
    Bork U; Lee WK; Kuchler A; Dittmar T; Thévenod F
    Am J Physiol Renal Physiol; 2010 Feb; 298(2):F255-65. PubMed ID: 19923412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage.
    Jackson JR; Gilmartin A; Imburgia C; Winkler JD; Marshall LA; Roshak A
    Cancer Res; 2000 Feb; 60(3):566-72. PubMed ID: 10676638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors.
    Tao ZF; Wang L; Stewart KD; Chen Z; Gu W; Bui MH; Merta P; Zhang H; Kovar P; Johnson E; Park C; Judge R; Rosenberg S; Sowin T; Lin NH
    J Med Chem; 2007 Apr; 50(7):1514-27. PubMed ID: 17352464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1.
    Yu Q; La Rose J; Zhang H; Takemura H; Kohn KW; Pommier Y
    Cancer Res; 2002 Oct; 62(20):5743-8. PubMed ID: 12384533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106.
    Walton MI; Eve PD; Hayes A; Valenti M; De Haven Brandon A; Box G; Boxall KJ; Aherne GW; Eccles SA; Raynaud FI; Williams DH; Reader JC; Collins I; Garrett MD
    Mol Cancer Ther; 2010 Jan; 9(1):89-100. PubMed ID: 20053762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Context-dependent cell cycle checkpoint abrogation by a novel kinase inhibitor.
    Massey AJ; Borgognoni J; Bentley C; Foloppe N; Fiumana A; Walmsley L
    PLoS One; 2010 Oct; 5(10):e13123. PubMed ID: 20976184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells.
    Landau HJ; McNeely SC; Nair JS; Comenzo RL; Asai T; Friedman H; Jhanwar SC; Nimer SD; Schwartz GK
    Mol Cancer Ther; 2012 Aug; 11(8):1781-8. PubMed ID: 22653969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carcinogen-induced S-phase arrest is Chk1 mediated and caffeine sensitive.
    Guo N; Faller DV; Vaziri C
    Cell Growth Differ; 2002 Feb; 13(2):77-86. PubMed ID: 11864911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radiation-induced phosphorylation of Chk1 at S345 is associated with p53-dependent cell cycle arrest pathways.
    Tian H; Faje AT; Lee SL; Jorgensen TJ
    Neoplasia; 2002; 4(2):171-80. PubMed ID: 11896572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of a screening assay for surrogate markers of CHK1 inhibitor-induced cell cycle release.
    Fanton CP; Rowe MW; Moler EJ; Ison-Dugenny M; De Long SK; Rendahl K; Shao Y; Slabiak T; Gesner TG; MacKichan ML
    J Biomol Screen; 2006 Oct; 11(7):792-806. PubMed ID: 17035625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological inactivation of CHK1 and WEE1 induces mitotic catastrophe in nasopharyngeal carcinoma cells.
    Mak JP; Man WY; Chow JP; Ma HT; Poon RY
    Oncotarget; 2015 Aug; 6(25):21074-84. PubMed ID: 26025928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350.
    Yin MB; Guo B; Vanhoefer U; Azrak RG; Minderman H; Frank C; Wrzosek C; Slocum HK; Rustum YM
    Mol Pharmacol; 2000 Mar; 57(3):453-9. PubMed ID: 10692484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of ATR-Chk1 pathway inhibitors that selectively target p53-deficient cells without directly suppressing ATR catalytic activity.
    Kawasumi M; Bradner JE; Tolliday N; Thibodeau R; Sloan H; Brummond KM; Nghiem P
    Cancer Res; 2014 Dec; 74(24):7534-45. PubMed ID: 25336189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel checkpoint 1 inhibitors.
    Prudhomme M
    Recent Pat Anticancer Drug Discov; 2006 Jan; 1(1):55-68. PubMed ID: 18221026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.